Barclays ups CVS Health to Buy on positive margin outlook
CVS Health Positioned For Medicare Margin Expansion And Market Share Gains, Says Barclays Analyst
Barclays upgraded CVS Health Inc (NYSE:CVS) on higher Pharmacy & Consumer Wellness (PCW) estimates as headwinds are offset by share gains, with further upside potential from CostVantage. Despite macroeconomic pressures impacting the retail pharmacy sector,
What’s next for health insurers
Stock in the healthcare provider Humana came under pressure again on Friday after the U.S. government released quality ...
Analyses of 2025 Medicare Advantage star ratings continue to pour in and not all of it bodes well for the conventional ...
Talk that CVS Health may break up its businesses would mean unraveling synergies already making the company a lot of money.
CVS Health is laying off nearly 3,000 "primarily corporate roles" in a cost-cutting move, the company confirmed to USA TODAY ...
About 40% of MA plans with prescription drug coverage will earn four or more stars, a dip from 42% this year, according to data released by the CMS.
CVS is reportedly conducting a strategic review and weighing options for separating some of the company’s businesses.
CVS Health (CVS) stock receives an upgrade from TD Cowen to Buy with a price target of $85, based on favorable Medicare ...
Discover why TD Cowen sees 35% upside in CVS Health stock, driven by Medicare Advantage improvements and bullish technical ...
Glenview Capital Management — a hedge fund that has been subject of certain media reports that it was pushing CVS Health ...
CVS Health stock is lower Tuesday on reports the healthcare company is conducting a strategic review of its operations, which ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback